These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. External contamination of antineoplastic drug containers from a Canadian wholesaler. Hilliquin D; Bussières JF J Oncol Pharm Pract; 2020 Mar; 26(2):423-427. PubMed ID: 31446868 [TBL] [Abstract][Full Text] [Related]
3. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760 [TBL] [Abstract][Full Text] [Related]
4. Environmental contamination with methotrexate in Canadian community pharmacies. Merger D; Tanguay C; Langlois É; Lefebvre M; Bussières JF J Am Pharm Assoc (2003); 2013; 53(4):423-6. PubMed ID: 23892817 [TBL] [Abstract][Full Text] [Related]
5. Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies. Doležalová L; Bláhová L; Kuta J; Hojdarová T; Kozáková Š; Bláha L Environ Sci Pollut Res Int; 2022 Apr; 29(18):26810-26819. PubMed ID: 34855176 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of surface contamination in a hospital hematology--oncology pharmacy. Touzin K; Bussières JF; Langlois E; Lefebvre M J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214 [TBL] [Abstract][Full Text] [Related]
7. Pilot study: External surface contamination of gemcitabine and 5-fluorouracil on drug packaging. Kåredal M; Özdemir J; Tinnert A; Wetterling M; Hedmer M J Oncol Pharm Pract; 2024 Jan; 30(1):9-14. PubMed ID: 36916178 [TBL] [Abstract][Full Text] [Related]
8. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. Sessink PJ; Connor TH; Jorgenson JA; Tyler TG J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932 [TBL] [Abstract][Full Text] [Related]
9. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
10. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study. Roland C; Caron N; Bussières JF J Occup Environ Hyg; 2017 Aug; 14(8):661-669. PubMed ID: 28574754 [TBL] [Abstract][Full Text] [Related]
11. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process. Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165 [TBL] [Abstract][Full Text] [Related]
12. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Crauste-Manciet S; Sessink PJ; Ferrari S; Jomier JY; Brossard D Ann Occup Hyg; 2005 Oct; 49(7):619-28. PubMed ID: 16126757 [TBL] [Abstract][Full Text] [Related]
13. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542 [TBL] [Abstract][Full Text] [Related]
14. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Connor TH; Anderson RW; Sessink PJ; Broadfield L; Power LA Am J Health Syst Pharm; 1999 Jul; 56(14):1427-32. PubMed ID: 10428450 [TBL] [Abstract][Full Text] [Related]
15. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Harrison BR; Peters BG; Bing MR Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258 [TBL] [Abstract][Full Text] [Related]
17. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies - the MEWIP project. Kiffmeyer TK; Tuerk J; Hahn M; Stuetzer H; Hadtstein C; Heinemann A; Eickmann U Ann Occup Hyg; 2013 May; 57(4):444-55. PubMed ID: 23125441 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of long-term data on surface contamination by antineoplastic drugs in pharmacies. Quartucci C; Rooney JPK; Nowak D; Rakete S Int Arch Occup Environ Health; 2023 Jul; 96(5):675-683. PubMed ID: 36877242 [TBL] [Abstract][Full Text] [Related]
19. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study. Palamini M; Dufour A; Therrien R; Delisle JF; Mercier G; Gagné S; Caron N; Bussières JF J Oncol Pharm Pract; 2020 Dec; 26(8):1864-1870. PubMed ID: 32138611 [TBL] [Abstract][Full Text] [Related]
20. Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results. Palamini M; Gagné S; Caron N; Bussières JF J Oncol Pharm Pract; 2020 Dec; 26(8):1921-1930. PubMed ID: 32114883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]